Vita 34 AG
XETRA:V3V
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.96
5.38
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Vita 34 AG
Vita 34 AG
Additional Paid In Capital
Vita 34 AG
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vita 34 AG
XETRA:V3V
|
Additional Paid In Capital
€41.1m
|
CAGR 3-Years
20%
|
CAGR 5-Years
11%
|
CAGR 10-Years
6%
|
|
|
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
Additional Paid In Capital
€3.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-2%
|
|
|
Fresenius SE & Co KGaA
XETRA:FRE
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
E
|
Euroeyes International Eye Clinic Ltd
HKEX:1846
|
Additional Paid In Capital
HK$658.4m
|
CAGR 3-Years
2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Synlab AG
XETRA:SYAB
|
Additional Paid In Capital
€2.9B
|
CAGR 3-Years
24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Fresenius Medical Care AG
XMUN:FME
|
Additional Paid In Capital
€3.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-2%
|
|
Vita 34 AG
Glance View
Vita 34 AG engages in the collection and storage of umbilical cord blood and stem cells. The company is headquartered in Leipzig, Sachsen and currently employs 124 full-time employees. The company went IPO on 2007-03-27. The firm is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected at the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. They also allow the growing of whole organs, such as the liver. On average, one out seven individuals, whose cells are stored, receives autologous stem cell transplant by the age of 70. The firm acts as a cord blood bank and is also engaged in research activities in the area of regenerative medicine, including curing the consequences of strokes and heart attacks. The firm operates in Germany, Spain and Denmark.
See Also
What is Vita 34 AG's Additional Paid In Capital?
Additional Paid In Capital
41.1m
EUR
Based on the financial report for Jun 30, 2024, Vita 34 AG's Additional Paid In Capital amounts to 41.1m EUR.
What is Vita 34 AG's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
6%
Over the last year, the Additional Paid In Capital growth was 39%. The average annual Additional Paid In Capital growth rates for Vita 34 AG have been 20% over the past three years , 11% over the past five years , and 6% over the past ten years .
You don't have any saved screeners yet
